Is Cellbxhealth PLC (ANPCF) a Buy, Sell, or Hold?
OTC : ANPCF
Cellbxhealth PLC
$0.0103 USD
-$0.01 (-48.24%)
- Volume
- 20K
- Average Volume
- 4
- Market Capitalization
- $3.38M
- P/E Ratio
- Dividend Yield
- %
- Price Target
- Year High
- $0.11
- Year Low
- $0.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
Industry, Sector & symbol
| Stock Exchange | OTC |
| CEO | Peter Michael Collins |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Current Symbol | ANPCF |
| CUSIP | None |
| CIK | 0001620678 |
| Web | https://cellbxhealth.com |
| Phone | 44 14 8334 3434 |
| Currency | USD |
| Employees | 119 |
| Country | GB |
Liquidity
| Debt-to-Equity Ratio | |
| Payout Ratio | |
| Current Ratio | |
| Quick Ratio | |
| Cash Ratio |
Sales & Book Value
| Annual Sales | $1.35M |
| Price / Sales | |
| Cash Flow | |
| Price / Cash Flow | |
| Price / Book |
Price Target and Rating
| Average Stock Price Forecast | |
| High Stock Price Forecast | |
| Low Stock Price Forecast | |
| Forecast Upside/Downside | % |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$0.0551 |
| Trailing P/E Ratio | |
| PEG Ratio | |
| P/E Growth | |
| Net Income | -$19.51M |
| Net Margin | % |
| Pretax Margin | % |
| Return on Equity | % |
| Return on Assets | % |
Financials Score
| AltmanZ Score | -35.58 |
| Piotroski Score | 2.00 |
| Working Capital | 3.72M |
| Total Assets | 7.75M |
| Ebit | -23M |
| Market Cap | 4.83M |
| Total Liabilities | 3.67M |
Poll Results
About Cellbxhealth PLC (OTC:ANPCF) Stock
CelLBxHealth plc, formerly known as ANGLE plc until its name change in October 2025, is a medical diagnostics enterprise established in 1994 and headquartered in Guildford, United Kingdom. The company is dedicated to developing advanced cancer diagnostic products, serving markets across the United Kingdom, Europe, North America, and other international regions. Its core offerings include the Parsortix PC1 and PR1 systems, which are innovative medical devices engineered to capture and retrieve intact circulating tumor cells (CTCs) from patient blood. Specifically, the PC1 system is designed for metastatic breast cancer samples, facilitating subsequent user-validated downstream analysis. CelLBxHealth also provides the Portrait+ CTC Staining kit, a laboratory solution for the identification, ... characterization, and enumeration of epithelial and mesenchymal CTCs with high analytical sensitivity and specificity, alongside the CellKeep Slide technology for CTC harvesting. In addition to these products, the company delivers a suite of laboratory services, including CTC enrichment and liquid biopsy analysis. Specialized assays are also available, such as Portrait Flex for immunofluorescence-based identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition, Portrait PD-L1 for CTC evaluation, and bespoke custom CTC assays. Furthermore, CelLBxHealth plc has forged strategic alliances, including a partnership with BioView Ltd to co-develop a human epidermal growth factor receptor 2 (HER2) assay kit for breast cancer, and an agreement with NuProbe USA, Inc. for the application of its pan-cancer next-generation sequencing (NGS) panel.
CelLBxHealth moves from cutting to converting
2026-07-15 04:56:13
The interim figures mark the point where CelLBxHealth PLC (AIM:CLBX, FRA:DWV) stops being a restructuring story and starts being a commercial one, says a note from Cavendish. The heavy lifting is done.
CelLBxHealth builds £3.5m weighted pipeline as revenue growth target held
2026-07-15 02:58:42
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the AIM-listed cancer diagnostics company, said its commercially weighted pipeline had built to £3.5 million, supported by rising engagement from pharmaceutical and diagnostic partners. It reiterated its forecast for revenue of at least £2.1 million for the 2026 financial year, growth of at least 50% on the prior year.
CelLBxHealth reaffirms revenue guidance
2026-07-14 02:54:43
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the cancer diagnostics company, has told shareholders it remains on track to deliver revenues of at least £2.1 million for 2026 as it searches for a new chief executive. The figure would represent a 50% increase on 2025.
Cavendish backs CelLBxHealth turnaround with buy rating, 4p target
2026-06-22 10:35:33
Cavendish remains bullish on CelLBxHealth PLC (AIM:CLBX, FRA:DWV) with a 'buy' rating and 4p price target in the wake of its prelims earlier. The AIM-listed biotech has completed a strategic reset centred on cost reduction and a shift towards partner-led commercialisation of its Parsortix platform.
CelLBxHealth guides for 50% revenue growth as partnership pipeline swells
2026-06-22 03:01:24
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the circulating tumour cell diagnostics company, expects revenues of at least £2.1 million in 2026, representing growth of at least 50% from last year's £1.4 million, underpinned by a commercial pipeline that has expanded 22% over the last quarter. The AIM-listed company has emerged from a year-long restructuring sharper and leaner, having cut its cost base substantially during 2025 and recruited new leadership to drive a partnership-focused strategy centred on pharmaceutical and diagnostic companies rather than research income.
CelLBxHealth strikes US clinical collaboration with AdventHealth cancer studies
2026-05-18 02:39:57
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the AIM-listed circulating tumour cell (CTC) diagnostics company, has secured a collaboration with AdventHealth, one of the largest faith-based health systems in the United States, to deploy its Parsortix platform in two clinical cancer studies. The trials, titled ACTION and SUNRISE, will use CelLBxHealth's technology to isolate and analyse CTCs from blood samples taken from patients undergoing treatment for colon, gastrointestinal and lung cancers.
Frequently Asked Questions
-
What is the current Cellbxhealth PLC (ANPCF) stock price?
-
Cellbxhealth PLC(OTC:ANPCF) stock price is $0.0103 in the last trading session. During the trading session, ANPCF stock reached the peak price of $0.10606 while $0.0103 was the lowest point it dropped to. The percentage change in ANPCF stock occurred in the recent session was --48.24% while the dollar amount for the price change in ANPCF stock was -$0.01.
-
ANPCF's industry and sector of operation?
-
The OTC listed ANPCF is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of ANPCF?
-
Cristina Ciccioli | Head of Assay Development
Michelle Munson | Chief of Staff
Sinéad Eithne Armstrong | Finance Director & Secretary
Peter Michael Collins | CEO & Director
Lauren Arthy-Miles | ESG Lead -
How many employees does ANPCF have?
-
Number of ANPCF employees currently stands at 119. ANPCF operates from Surrey Research Park, Guildford, SU GU2 7AF, GB.
-
Link for ANPCF official website?
-
Official Website of ANPCF is: https://cellbxhealth.com
-
How do I contact ANPCF?
-
ANPCF could be contacted at phone #44 14 8334 3434 and can also be accessed through its website. ANPCF operates from Surrey Research Park, Guildford, SU GU2 7AF, GB.
-
How many shares of ANPCF are traded daily?
-
The average number of ANPCF shares traded daily for last 3 months was 4.
-
What is the market cap of ANPCF currently?
-
The market value of ANPCF currently stands at $3.38M with its latest stock price at $0.0103